挽救性高强度聚焦超声治疗低剂量率近距离放疗后局部复发前列腺癌的肿瘤学与功能结局
该II期临床研究纳入2003至2015年间50例低剂量率近距离放疗后局部复发前列腺癌患者,接受挽救性高强度聚焦超声治疗。中位随访4.6年,6年无治疗失败生存率为41%,总生存率93%,肿瘤特异生存率98%。近距离放疗后参数较外照射后参数降低2-3级尿失禁发生率(34% vs 62%,P=0.015),半腺消融较全腺消融显著降低并发症。
要点
- 6年无治疗失败生存率41%、无进展生存率45%、总生存率93%、肿瘤特异生存率98%、无转移生存率80%
- 近距离放疗后参数较外照射后参数降低2-3级尿失禁(34% vs 62%,P=0.015)
- 半腺消融较全腺消融显著降低尿失禁(14% vs 54%,P<0.001)、膀胱出口梗阻(13% vs 46%,P=0.03)和≥III级并发症(13% vs 63%,P=0.001)
核心结论
- 挽救性高强度聚焦超声治疗低剂量率近距离放疗后局部复发前列腺癌可获得较好的生存率,但伴随显著并发症。
- 专用近距离放疗后参数和半腺消融可提高治疗安全性。
研究设计与样本
- 临床II期研究(2003-2015年),连续纳入50例低剂量率近距离放疗后局部复发前列腺癌患者,接受挽救性高强度聚焦超声治疗。
- 13例使用外照射后参数,37例使用近距离放疗后参数;35例全腺消融,15例半腺消融(2009年起用于单侧前列腺癌)。
- 主要目标为评估肿瘤学结局(无治疗失败生存、无进展生存、总生存、肿瘤特异生存、无转移生存率),次要目标为不良事件、控尿功能和勃起功能。
- 采用Kaplan-Meier分析估计肿瘤学结局。
主要发现
- 中位随访4.6年,挽救性高强度聚焦超声后中位前列腺特异抗原水平为0.3 ng/mL。
- 6年时无治疗失败生存率41%、无进展生存率45%、总生存率93%、肿瘤特异生存率98%、无转移生存率80%。
- 近距离放疗后参数组较外照射后参数组2-3级尿失禁发生率降低(34% vs 62%,P=0.015)。
- 半腺消融组较全腺消融组尿失禁发生率降低(14% vs 54%,P<0.001)、膀胱出口梗阻发生率降低(13% vs 46%,P=0.03)、≥III级并发症发生率降低(13% vs 63%,P=0.001)。
- 挽救性高强度聚焦超声前25例患者国际勃起功能指数五項版评分≥17,12个月时48%维持该评分。
临床怎么用
- 原文未据此给出推荐。
- 作者结论认为挽救性高强度聚焦超声治疗低剂量率近距离放疗后局部复发前列腺癌可获得较好生存率,但伴随显著并发症;专用近距离放疗后参数和半腺消融可提高治疗安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the oncological and functional outcomes of salvage high-intensity focused ultrasound (S-HIFU) for locally recurrent prostate cancer after low-dose-rate (LDR) brachytherapy. PATIENTS AND METHODS: Clinical phase II studies (2003-2015) included 50 consecutive patients with post-brachytherapy local recurrence treated by S-HIFU. S-HIFU was performed with post-external beam radiotherapy (EBRT) parameters and, since 2008, with specific post-brachytherapy parameters. Treatments were whole-gland ablation and, since 2009, hemi-ablation in cases of unilateral prostate cancer. The primary objective was to assess oncological outcomes: treatment failure-free survival, progression-free survival (PFS), overall survival (OS), cancer-specific survival (CSS), and metastasis-free survival (MFS) rates. The secondary objective was to evaluate adverse events, continence, and erectile function. Kaplan-Meier analysis estimated oncological outcomes. RESULTS: In all, 13 patients were treated with post-EBRT parameters, 37 with post-brachytherapy parameters, 35 with whole-gland treatment, and 15 with hemi-ablation. The median follow-up was 4.6 years. After S-HIFU, the median prostate-specific antigen level was 0.3 ng/mL. At 6 years, treatment failure-free survival, PFS, OS, CSS, and MFS rates were 41%, 45%, 93%, 98%, and 80%, respectively. Post-brachytherapy compared with post-EBRT parameters reduced Grade 2-3 incontinence (34% vs 62%, P = 0.015). Incontinence, bladder outlet obstruction and Grade ≥III complications were significantly reduced with hemi-ablation compared with whole-gland treatment (14% vs 54%, P < 0.001; 13% vs 46%, P = 0.03; 13% vs 63%, P = 0.001; respectively). Before S-HIFU, 25 patients had a five-item version of the International Index of Erectile Function score of ≥17, which was maintained in 48% at 12 months. CONCLUSION: S-HIFU for locally recurrent prostate cancer after LDR brachytherapy is associated with favourable survival rates at a price of significant morbidity. Dedicated post-brachytherapy parameters and hemi-ablation improve the safety of the treatment.
引用
- Hostiou T, Gelet A, Chapelon JY, et al. Salvage high-intensity focused ultrasound for locally recurrent prostate cancer after low-dose-rate brachytherapy: oncological and functional outcomes. BJU Int. 2019. PMID: 31148367. doi:10.1111/bju.14838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。